Pluriomics Stem Cell technology

Pluriomics BV partners with Pivot Park Screening Centre to offer ultra High Throughput Screening for Cardiovascular drug discovery services

Leiden and Oss, The Netherlands, May 30th, 2017
Pluriomics and Pivot Park Screening Centre today announced a collaboration to improve Pluriomics’ cardiovascular drug discovery service offerings and to expand Pivot Park Screening Centre’s knowledge about new and innovative assay technologies used to accelerate drug discoveries. Giving Pluriomics access to the Screening Centre’s ultra High Throughput Screening (uHTS) capability, this collaboration will serve Pluriomics mission which is to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates.

Pluriomics is a leading expert in human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug discovery. Pluriomics’ developed a proprietary technology to differentiate fully functional human iPSC-derived cardiomyocytes exhibiting unique electrophysiological characteristics that make them exceptionally well-suited for disease modeling and phenotypic screening. Indeed, implemented in various contractility-, biochemistry- and electrophysiology-based assays, Pluriomics’ Pluricyte® Cardiomyocytes contribute to improve drug safety and efficacy screenings. Combining Pluriomics unique cardiovascular models and cardiovascular expertise with Pivot Park Screening Centre’s uHTS platform and extensive uHTS and assay development expertise will allow Pluriomics not only to dramatically improve the throughput of its drug efficacy screening using automation and miniaturization, but also to access a library of 300,000 high quality drug-like compounds to accelerate its developments and programs to advance cardiovascular research and development which will be available for cardiovascular drug discovery service projects.

Stefan Braam, CEO of Pluriomics BV, commented: “This collaboration expands Pluriomics offerings in a new direction as it will allow us to expand our service offerings with screening capabilities ranging from a few hundreds of compounds to millions of compounds. We believe that the combination of the high quality and unique characteristic of our cells with HTS will enable phenotypic screening at any throughput, thereby contributing to better and more efficient drug discovery. We look forward to working with Pivot Park team!”

Helma Rutjes, COO of Pivot Park Screening Centre added: “Through this collaboration we are able to jointly accelerate the discovery of new medicines for a healthier society. By learning from each other and make use of each other’s expertise and facilities this will be a partnership of great value directly for both parties and indirectly for our future and current partners who are using our assay development and ultra High Throughput Screening facilities.”


For more information please contact:
PluriomicsPivot Park Screening Centre
celine.hechard(at)pluriomics.comscreeningsecretariaat(at)ppscreeningcentre.com
+31 (0)71 332 2230+31 (0) 412 846050
                                                           

About Pluriomics

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.

Pluriomics offers unique cardiac drug discovery and safety assessment solutions based on its best-in-class human iPSC-derived cardiomyocyte cellular assays. The company aims to contribute to the efficiency of the drug discovery and development process by delivering products and services for early discovery and safety assessment.

The company is backed by private investors, Venture Funds and strategic investment from regional investment funds (Vesalius Biocapital, InnovationQuarter, S.R.I.W, SFPI-FPIM, Sambrinvest).

Pluriomics is based in Leiden, The Netherlands and in Gosselies, Belgium.

For more information please visit www.pluriomics.com 


About Pivot Park Screening Centre

With our partners, we accelerate the discovery of new medicines for a healthier society. Pivot Park Screening Centre (PPSC) provides drug discovery services in the field of assay development, lab automation and (ultra) High Throughput Screening ((u)HTS) to find new leads for drug development. PPSC specializes in the screening of large libraries for pharma companies. In addition, PPSC is the central screening site in the European Lead Factory, collaborating with a large number of academia and SME’s.  The screening facility includes state-of-the-art robotic systems and an extensive collection of 300,000 high quality drug-like compounds. The open access facilities provide instrumentation for hit-to-lead testing and technology development. Pivot Park Screening Centre is based at Pivot Park in Oss, the Netherlands.

For more information please visit www.ppscreeningcentre.com

To view this press release as a PDF file, click here